Crombie AL - Search Results

1

Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.

Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Perros P, et al. Among authors: crombie al. Clin Endocrinol (Oxf). 1993 Apr;38(4):367-72. doi: 10.1111/j.1365-2265.1993.tb00516.x. Clin Endocrinol (Oxf). 1993. PMID: 8319368

2

Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.

Hart RH, Kendall-Taylor P, Crombie A, Perros P. Hart RH, et al. J Ocul Pharmacol Ther. 2005 Aug;21(4):328-36. doi: 10.1089/jop.2005.21.328. J Ocul Pharmacol Ther. 2005. PMID: 16117697

3

Azathioprine in the treatment of thyroid-associated ophthalmopathy.

Perros P, Weightman DR, Crombie AL, Kendall-Taylor P. Perros P, et al. Among authors: crombie al. Acta Endocrinol (Copenh). 1990 Jan;122(1):8-12. doi: 10.1530/acta.0.1220008. Acta Endocrinol (Copenh). 1990. PMID: 2305608

4

Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.

Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Kendall-Taylor P, et al. Among authors: crombie al. BMJ. 1988 Dec 17;297(6663):1574-8. doi: 10.1136/bmj.297.6663.1574. BMJ. 1988. PMID: 2906260 Free PMC article.

5

Natural history of thyroid associated ophthalmopathy.

Perros P, Crombie AL, Kendall-Taylor P. Perros P, et al. Among authors: crombie al. Clin Endocrinol (Oxf). 1995 Jan;42(1):45-50. doi: 10.1111/j.1365-2265.1995.tb02597.x. Clin Endocrinol (Oxf). 1995. PMID: 7889631

6

The long-term effects of megavoltage radiotherapy as sole or combined therapy for large prolactinomas: studies with high definition computerized tomography.

Johnston DG, Hall K, Kendall-Taylor P, Ross WM, Crombie AL, Cook DB, Watson MJ. Johnston DG, et al. Among authors: crombie al. Clin Endocrinol (Oxf). 1986 Jun;24(6):675-85. doi: 10.1111/j.1365-2265.1986.tb01664.x. Clin Endocrinol (Oxf). 1986. PMID: 3098457

7

An evaluation of supervoltage orbital irradiation for Graves' ophthalmopathy.

Teng CS, Crombie AL, Hall R, Ross WM. Teng CS, et al. Among authors: crombie al. Clin Endocrinol (Oxf). 1980 Dec;13(6):545-51. doi: 10.1111/j.1365-2265.1980.tb03422.x. Clin Endocrinol (Oxf). 1980. PMID: 6784979

8

Hyperprolactinaemia in men-response to bromocriptine therapy.

Prescott RW, Johnston DG, Kendall-Taylor P, Crombie A, Hall K, McGregor A, Hall R. Prescott RW, et al. Lancet. 1982 Jan 30;1(8266):245-8. doi: 10.1016/s0140-6736(82)90975-8. Lancet. 1982. PMID: 6120274

9

Hyperprolactinemia. Long-term effects of bromocriptine.

Johnston DG, Prescott RW, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB. Johnston DG, et al. Among authors: crombie al. Am J Med. 1983 Nov;75(5):868-74. doi: 10.1016/0002-9343(83)90418-7. Am J Med. 1983. PMID: 6638052

10

Critical study of 5 per cent guanethidine in ocular manifestations of Graves's disease.

Cartlidge NE, Crombie AL, Anderson J, Hall R. Cartlidge NE, et al. Among authors: crombie al. Br Med J. 1969 Dec 13;4(5684):645-7. doi: 10.1136/bmj.4.5684.645. Br Med J. 1969. PMID: 4902494 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page